VWR Corporation (NASDAQ:VWR) Expected to Post Quarterly Sales of $1.17 Billion
Wall Street analysts expect VWR Corporation (NASDAQ:VWR) to report $1.17 billion in sales for the current quarter, according to Zacks. Four analysts have made estimates for VWR Corporation’s earnings, with the lowest sales estimate coming in at $1.15 billion and the highest estimate coming in at $1.19 billion. VWR Corporation posted sales of $1.14 billion in the same quarter last year, which would indicate a positive year over year growth rate of 2.6%. The business is expected to announce its next earnings report on Thursday, November 2nd.
According to Zacks, analysts expect that VWR Corporation will report full year sales of $1.17 billion for the current fiscal year, with estimates ranging from $4.58 billion to $4.70 billion. For the next year, analysts anticipate that the firm will report sales of $4.79 billion per share, with estimates ranging from $4.74 billion to $4.86 billion. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for VWR Corporation.
VWR Corporation (NASDAQ:VWR) last announced its quarterly earnings data on Monday, July 31st. The medical research company reported $0.49 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.45 by $0.04. The business had revenue of $1.18 billion during the quarter, compared to analysts’ expectations of $1.16 billion. VWR Corporation had a return on equity of 15.54% and a net margin of 3.12%. The firm’s quarterly revenue was up 2.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.42 earnings per share.
Several brokerages have issued reports on VWR. TheStreet raised VWR Corporation from a “c” rating to a “b-” rating in a research report on Wednesday, April 19th. William Blair cut VWR Corporation from an “outperform” rating to a “market perform” rating in a research report on Friday, May 5th. Zacks Investment Research raised VWR Corporation from a “hold” rating to a “buy” rating and set a $37.00 target price on the stock in a research report on Tuesday, May 16th. Finally, BidaskClub cut VWR Corporation from a “hold” rating to a “sell” rating in a research report on Sunday, July 16th. Three investment analysts have rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company’s stock. VWR Corporation has an average rating of “Hold” and a consensus price target of $30.50.
Several hedge funds have recently bought and sold shares of VWR. SG Americas Securities LLC acquired a new stake in VWR Corporation during the second quarter worth $531,000. Capital Insight Partners LLC boosted its stake in VWR Corporation by 4.4% in the second quarter. Capital Insight Partners LLC now owns 46,748 shares of the medical research company’s stock worth $1,543,000 after buying an additional 1,962 shares during the last quarter. Exane Asset Management acquired a new stake in VWR Corporation during the second quarter worth $1,059,000. Aperio Group LLC boosted its stake in VWR Corporation by 84.4% in the second quarter. Aperio Group LLC now owns 49,608 shares of the medical research company’s stock worth $1,638,000 after buying an additional 22,712 shares during the last quarter. Finally, Public Employees Retirement System of Ohio boosted its stake in VWR Corporation by 3.4% in the first quarter. Public Employees Retirement System of Ohio now owns 31,762 shares of the medical research company’s stock worth $896,000 after buying an additional 1,031 shares during the last quarter.
VWR Corporation (VWR) opened at 33.00 on Friday. The stock has a market cap of $4.35 billion, a PE ratio of 30.56 and a beta of 1.19. VWR Corporation has a 52 week low of $24.42 and a 52 week high of $37.25. The firm’s 50-day moving average price is $32.99 and its 200-day moving average price is $29.83.
VWR Corporation Company Profile
VWR Corporation is a provider of product and service solutions to laboratory and production customers. The Company offers a portfolio of branded and private label laboratory products, services and solutions to the life science, general research and applied markets. The Company operates in two segments: Americas and EMEA-APAC.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for VWR Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VWR Corporation and related companies with MarketBeat.com's FREE daily email newsletter.